Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313377539> ?p ?o ?g. }
- W4313377539 endingPage "122488" @default.
- W4313377539 startingPage "122488" @default.
- W4313377539 abstract "Reduced drug uptake and elevated drug efflux are two major mechanisms in cancer multidrug resistance (MDR). In the present study, a new multistage O2-producing liposome with NAG/R8-dual-ligand and stimuli-responsive dePEGylation was developed to address the abovementioned issues simultaneously. The designed C-NAG-R8-PTXL/MnO2-lip could also achieve magnetic resonance imaging (MRI)-guided synergistic chemodynamic/chemotherapy (CDT/CT). In vitro and in vivo studies showed that C-NAG-R8-PTXL/MnO2-lip enhanced circulation time by PEG and targeted the tumor site. After tumor accumulation, endogenous l-cysteine was administered, and the PEG-attached disulfide bond was broken, resulting in the dissociation of PEG shells. The previously hidden positively charged R8 by different lengths of PEG chains was exposed and mediated efficient internalization. In addition, the oxygen (O2) generated by C-NAG-R8-PTXL/MnO2-lip relieved the hypoxic environment within the tumor, thus reducing the efflux of chemotherapeutic drug. O2 was able to burst liposomes and triggered the release of PTXL. The toxic hydroxyl radical (·OH), which was produced by H2O2 and Mn2+, strengthened CDT/CT. C-NAG-R8-PTXL/MnO2-lip was also used as MRI contrast agent, which blazed the trail to rationally design theranostic agents for tumor imaging." @default.
- W4313377539 created "2023-01-06" @default.
- W4313377539 creator A5010710324 @default.
- W4313377539 creator A5012313693 @default.
- W4313377539 creator A5027395548 @default.
- W4313377539 creator A5046486294 @default.
- W4313377539 creator A5046717491 @default.
- W4313377539 creator A5084391656 @default.
- W4313377539 creator A5084988482 @default.
- W4313377539 creator A5090330947 @default.
- W4313377539 date "2023-01-01" @default.
- W4313377539 modified "2023-10-14" @default.
- W4313377539 title "Multistage O2-producing liposome for MRI-guided synergistic chemodynamic/chemotherapy to reverse cancer multidrug resistance" @default.
- W4313377539 cites W1507021713 @default.
- W4313377539 cites W2015202374 @default.
- W4313377539 cites W2074049796 @default.
- W4313377539 cites W2291205197 @default.
- W4313377539 cites W2320265903 @default.
- W4313377539 cites W2562206371 @default.
- W4313377539 cites W2593691629 @default.
- W4313377539 cites W2601555852 @default.
- W4313377539 cites W2738205912 @default.
- W4313377539 cites W2745048361 @default.
- W4313377539 cites W2793503277 @default.
- W4313377539 cites W2896519829 @default.
- W4313377539 cites W2903443412 @default.
- W4313377539 cites W2953634981 @default.
- W4313377539 cites W2962065294 @default.
- W4313377539 cites W2965878908 @default.
- W4313377539 cites W2966824455 @default.
- W4313377539 cites W2981856628 @default.
- W4313377539 cites W2987117350 @default.
- W4313377539 cites W2995340618 @default.
- W4313377539 cites W2997507675 @default.
- W4313377539 cites W2998652904 @default.
- W4313377539 cites W2999585670 @default.
- W4313377539 cites W3004836711 @default.
- W4313377539 cites W3010663981 @default.
- W4313377539 cites W3013736442 @default.
- W4313377539 cites W3040057801 @default.
- W4313377539 cites W3043119713 @default.
- W4313377539 cites W3044869855 @default.
- W4313377539 cites W3083326915 @default.
- W4313377539 cites W3091980736 @default.
- W4313377539 cites W3104458648 @default.
- W4313377539 cites W3109275210 @default.
- W4313377539 cites W3119005666 @default.
- W4313377539 cites W3130526193 @default.
- W4313377539 cites W3134767460 @default.
- W4313377539 cites W3137240378 @default.
- W4313377539 cites W3155212653 @default.
- W4313377539 cites W3162931030 @default.
- W4313377539 cites W3167353027 @default.
- W4313377539 cites W3174237030 @default.
- W4313377539 cites W3175761267 @default.
- W4313377539 cites W3208086214 @default.
- W4313377539 cites W3213860132 @default.
- W4313377539 cites W3213973662 @default.
- W4313377539 cites W3216052117 @default.
- W4313377539 cites W4280535001 @default.
- W4313377539 cites W4306693839 @default.
- W4313377539 cites W4307989497 @default.
- W4313377539 cites W4308689106 @default.
- W4313377539 cites W4308915407 @default.
- W4313377539 doi "https://doi.org/10.1016/j.ijpharm.2022.122488" @default.
- W4313377539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36521638" @default.
- W4313377539 hasPublicationYear "2023" @default.
- W4313377539 type Work @default.
- W4313377539 citedByCount "3" @default.
- W4313377539 countsByYear W43133775392023 @default.
- W4313377539 crossrefType "journal-article" @default.
- W4313377539 hasAuthorship W4313377539A5010710324 @default.
- W4313377539 hasAuthorship W4313377539A5012313693 @default.
- W4313377539 hasAuthorship W4313377539A5027395548 @default.
- W4313377539 hasAuthorship W4313377539A5046486294 @default.
- W4313377539 hasAuthorship W4313377539A5046717491 @default.
- W4313377539 hasAuthorship W4313377539A5084391656 @default.
- W4313377539 hasAuthorship W4313377539A5084988482 @default.
- W4313377539 hasAuthorship W4313377539A5090330947 @default.
- W4313377539 hasConcept C10138342 @default.
- W4313377539 hasConcept C12554922 @default.
- W4313377539 hasConcept C133936738 @default.
- W4313377539 hasConcept C139770010 @default.
- W4313377539 hasConcept C141071460 @default.
- W4313377539 hasConcept C150903083 @default.
- W4313377539 hasConcept C162324750 @default.
- W4313377539 hasConcept C170493617 @default.
- W4313377539 hasConcept C178790620 @default.
- W4313377539 hasConcept C185154212 @default.
- W4313377539 hasConcept C185592680 @default.
- W4313377539 hasConcept C200082930 @default.
- W4313377539 hasConcept C202751555 @default.
- W4313377539 hasConcept C207001950 @default.
- W4313377539 hasConcept C2776694085 @default.
- W4313377539 hasConcept C2779081379 @default.
- W4313377539 hasConcept C2779820397 @default.
- W4313377539 hasConcept C501593827 @default.
- W4313377539 hasConcept C502942594 @default.